Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)

View Full Paper
Ask AI
Bookmark
Share

Authors

ZQZhengzi QianWLWei LiLQLihua Qiu

Discussion

Loading...

Member takes

Overview

Phase II trial shows 84.4% CR and over 90% MRD negativity in untreated FL patients, suggesting a new treatment paradigm.

Key Points

  • 84.4% complete response achieved after 4 cycles of zanubrutinib-enhanced G-CHOP, indicating high efficacy in follicular lymphoma.
  • 90.6% of patients demonstrated minimal residual disease negativity via ctDNA clearance, showing robust molecular responses post-treatment.
  • Observational analysis across treatment cycles assessed using standard G-CHOP and zanubrutinib with pegfilgrastim prophylaxis.
  • This MRD-guided paradigm highlights significant potential for precision chemotherapy in high-risk patients.'],'simple_explanation':

Cite This Study

Qian et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e01chttps://doi.org/10.1182/blood-2025-5380
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  3. 3Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  4. 4Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma2025
  5. 5A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis2025